Use of formularies could increase use of biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Use of formularies could increase use of biosimilars

Biosimilares/Investigación | Posted 14/02/2014 0 Post your comment

Whether or not the US Food and Drug Administration (FDA) permits automatic substitution of biosimilars, healthcare systems can still consider using formularies as a way to increase the use of more affordable biosimilars [1].

The formulary tool of therapeutic interchange can be used to exchange therapeutic alternatives according to approved written guidelines or protocols within a formulary system.

Therapeutic interchange programmes are already in place for a variety of biologicals. For example, in the case of erythropoiesis-stimulating agents (ESAs), automatic interchange programmes exist that convert orders for multiple ESA products to orders for a single ESA. This simplifies the formulary and consolidates the market share of one product in order to improve contracting and lower overall costs. Similar systems are also in place for human insulin and intravenous immune globulin.

Criteria that should be considered when setting up a therapeutic interchange programme include:

Including products considered therapeutically equivalent in terms of safety and efficacy
Potential savings to be made
Developing a clear process for interchange
Prescribers having sufficient knowledge and understanding of the products
The ability to ‘opt out’ under certain circumstances
The ability to assess the outcomes of therapy with the different products

In order to assure the appropriate use of biosimilars formulary management the following factors should also be considered:

Data on efficacy and safety
Indications
Potential for immunogenicity
Appropriate naming and labelling
Pharmacovigilance plan
The need for physician and patient education

Payers will undoubtedly provide significant incentives to use biosimilars in order to reduce costs. These may include significant co-payment or co-insurance premiums for use of an originator product when a biosimilar is available. Pharmacists will therefore need to be aware of both FDA and state laws when determining whether substitution is possible.

Conflict of interest
The authors of the research paper [1] declared that there were no conflicts of interest.

Editor’s comment

If you are interested in contributing a research paper inGaBI Journal, please send us your submission here.

If you would like to receive a PDF copy* of the Lucio article [1], please send us an email.

^{*For profit organizations subjected to a fee}

Related articles

US state legislation on biosimilars substitution

Efficacy, extrapolation and interchangeability of biosimilars

Biosimilar substitution in the EU

Reference

1. Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: implications for health-system pharmacists. Am J Health Syst Pharm. 2013;70(22):2004-17.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.